New adaptive radiation trial aims to cut prostate cancer treatment time without sacrificing quality of life

NCT ID NCT06355050

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing a new type of radiation therapy for early-stage prostate cancer that delivers very high doses in just a few sessions. The radiation machine adjusts the beam daily based on the patient's anatomy, aiming to protect healthy tissue. Researchers will track quality of life and side effects in 150 patients across Germany and compare them to standard radiation approaches.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
ultrahypofractionated adaptive radiation therapy (Varian Ethos device)
What this could lead to
If successful, this could offer a shorter, more precise radiation treatment for early prostate cancer with fewer side effects and better quality of life.
What could go wrong
This is an early-phase observational study with no control group, so results may not prove superiority over standard radiation. Side effects from high-dose radiation remain possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADAPTIVE RADIOTHERAPY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Department of Radiotherapy and Radiation Oncology, Jena University Hospital

    RECRUITING

    Jena, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.